Pharmaceuticals

NCPC

NCPC released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 2.153 B, actual EPS CNY 0.021

NCPC FY2026 Q1 Earnings Release Scheduled for April 25 After-Market BJT

NCPC released FY2025 Annual Earnings on April 17 After-Market (BJT), Actual Revenue CNY 9.242 B (Forecast CNY 10.44 B), Actual EPS CNY 0.107 (Forecast CNY 0.11)

NCPC released FY2025 Q4 earnings on April 17 After-Market (BJT), actual revenue CNY 1.757 B, actual EPS CNY 0.0146

NCPC to Release FY2025 Earnings on April 18 After-Market (BJT), Forecast Revenue CNY 10.44 B, EPS CNY 0.11

NCPC released FY2025 9 Months Earnings on October 24 During-Market (BJT), actual revenue CNY 7.485 B, actual EPS CNY 0.092

NCPC released FY2025 Q3 earnings on October 24 During-Market (BJT), actual revenue CNY 2.21 B, actual EPS CNY 0.0201

NCPC to Release FY2025 Q3 Earnings Report on October 25, 2025 During-Market (BJT)

NCPC released FY2025 Q2 earnings on August 13 After-Market (BJT), actual revenue CNY 2.701 B, actual EPS CNY 0.0379

NCPC released FY2025 Semi-Annual Earnings on August 13 After-Market (BJT), actual revenue CNY 5.275 B, actual EPS CNY 0.0719

Huabei Pharmaceutical Reports 124 Million Yen Profit and Advances in Pain Drug First Generic and Raw Material Internationalization

NCPC FY2025 Semi-Annual Earnings Release on August 14, 2025 (BJT)

Huasheng Company Obtains CEP Certification for Polymyxin B Sulfate API

Huabei Pharmaceutical's net profit increased by 72% in the first half of the year

Huabei Pharmaceutical Subsidiary Obtains Certificate for Ceftazime Avibactam

North China Pharmaceutical Obtains Approval for Polymyxin B Sulfate Launch

Huabei Pharmaceutical Receives Approval for 100mg Vitamin B6 Injection

Huabei Pharmaceutical Obtains Certificate for Injection Sulfaconazole

North China Pharmaceutical Submits New Trademark Application

North China Pharmaceutical Received SSE Inquiry Due to Missing Deposits

600812

NCPC announced on October 24th that it achieved an operating income of 2.21 billion yuan in the third quarter of 2025, a year-on-year decrease of 5.12%; the net profit attributable to shareholders of the listed company was 35.0066 million yuan, a year-on-year increase of 14.85%; basic earnings per share were 0.02 yuan. In the first three quarters, it achieved an operating income of 7.485 billion yuan, a year-on-year decrease of 1%; the net profit attributable to shareholders of the listed company was 159 million yuan, a year-on-year increase of 54.69%; basic earnings per share were 0.092 yuan

Zhitong

NCPC: In the third quarter, the net profit attributable to the parent company was 35.0066 million yuan, an increase of 14.85% year-on-year

NCPC announced that its wholly-owned subsidiary Hebei Huamin Pharmaceutical Co., Ltd. has received the "Approval Notice for the Listing Application of Chemical Raw Materials" for Cefprozil issued by the National Medical Products Administration. Cefprozil is a second-generation cephalosporin antibiotic with advantages such as strong antibacterial activity, resistance to penicillinase, and good clinical efficacy, and can be used to treat bronchitis or other bacterial infections

NCPC: Wholly-owned subsidiary receives approval notice for the listing application of Cefoperazone chemical raw materials

NCPC's wholly-owned subsidiary, Southern Company, has obtained the drug registration certificate for injectable imipenem and cilastatin sodium issued by the National Medical Products Administration. This drug is a compound formulation suitable for infections caused by various sensitive bacteria. Southern Company submitted the application in June 2024 and received the registration certificate in September 2025, with a total R&D investment of 5.2243 million yuan. It is expected that sales will reach 2.3 billion yuan in 2024, with a sales volume of approximately 20 million units

NCPC: Southern Company Obtains Drug Registration Certificate

NCPC recently obtained the drug registration certificate for injectable Vancomycin Hydrochloride (0.5g) approved by the National Medical Products Administration. This certificate indicates that the product meets the basic access conditions for centralized procurement bidding and has an efficacy equivalent to the original research product, further improving the company's product structure in the field of anti-infection

NCPC has obtained the drug registration certificate for injectable vancomycin hydrochloride (0.5g)

NCPC released its half-year performance for 2025, with revenue of 5.275 billion yuan, a year-on-year increase of 0.84%; net profit attributable to the parent company of 123 million yuan, a year-on-year increase of 71.56%; net profit excluding non-recurring items of 120 million yuan, a year-on-year increase of 120.69%; basic earnings per share of 0.072 yuan. The company reduced costs and improved profitability through lean management and budget control. The net cash flow from operating activities decreased due to receiving land compensation of 410 million yuan

NCPC released its semi-annual performance report, with a net profit attributable to the parent company of 123 million yuan, a year-on-year increase of 71.56%

NCPC recently obtained the drug registration certificate for Adenosylcobalamin Capsules (0.5mg) issued by the National Medical Products Administration. This drug can inhibit abnormal fat synthesis in nerve myelin, promote nerve repair, reduce abnormal TNFα levels, and participate in cellular metabolism, mainly used for the prevention and treatment of vitamin B12 deficiency and related diseases

NCPC: Adenosylcobalamin Capsules (0.5mg) have obtained the drug registration certificate

NCPC's wholly-owned subsidiary, Huasheng Company, has obtained the European Pharmacopoeia suitability certificate for Sulfate Polymyxin B chemical raw materials issued by the European Medicines Agency. This drug is used to treat acute infections caused by sensitive strains such as Pseudomonas aeruginosa, particularly suitable for urinary tract, meningitis, and bloodstream infections

NCPC's subsidiary has obtained the CEP certificate for Sulfomycetin B active pharmaceutical ingredient

NCPC expects its net profit attributable to shareholders to be approximately 123.5 million yuan in the first half of 2025, a year-on-year increase of 72%. The performance increase is mainly attributed to the company's deepening budget control, implementing lean management, reducing procurement costs, and various expenses, thereby improving profitability

NCPC issued a preliminary increase, expecting a net profit attributable to the parent company of approximately 123.5 million yuan in the first half of the year, an increase of 72% year-on-year

NCPC's subsidiary Huasheng Company recently received the notice of approval for the marketing application of Sulfate Polymyxin B chemical raw materials from the National Medical Products Administration. This drug is used to treat acute infections caused by sensitive strains of Pseudomonas aeruginosa, particularly suitable for urinary tract, meningitis, and bloodstream infections. It can be used for the treatment of severe infections when other drugs with lower potential toxicity are ineffective or contraindicated

NCPC's subsidiary has received the approval notice for the marketing application of Sulfate Polymyxin B chemical raw materials

NCPC's wholly-owned subsidiary Hebei Huamin Pharmaceutical Co., Ltd. recently obtained the drug registration certificate for injectable Ceftazidime Avibactam (2.5g) issued by the National Medical Products Administration. This drug is indicated for the treatment of Gram-negative bacterial infections, including complicated intra-abdominal infections and hospital-acquired pneumonia

NCPC(600812.SH)